Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis

Toxicologic Pathology

Volumn 38, Issue 1, 2010, Pages 123-130

  Hawes, Jessica J ^a   Reilly, Karlyne M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Astrocytoma; Bioluminescence; Glioblastoma; Malignant peripheral nerve sheath tumor; Mouse models of cancer; Neurofibromatosis

Indexed keywords

LUCIFERASE; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOLUMINESCENCE; CANCER GENETICS; CANCER RESEARCH; CARCINOGENESIS; DISEASE ACTIVITY; DISEASE COURSE; HAPLOTYPE; IN VIVO STUDY; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TUMOR GROWTH; ANIMAL; ARTICLE; ASTROCYTOMA; C57BL MOUSE; CYTOMEGALOVIRUS; DISEASE MODEL; GENETICS; HUMAN; LUMINESCENCE; METHODOLOGY; NERVE SHEATH TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALIA; MUS;

ANIMALS; ASTROCYTOMA; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; GENES, P53; HUMANS; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSES; PROMOTER REGIONS, GENETIC;

EID: 77952301058     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309357075     Document Type: Review

References (35)

1. Bajenaru, M. L., Hernandez, M. R., Perry, A., Zhu, Y., Parada, L. F., Garbow, J. R., and Gutmann, D. H. (2003). Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63 (24), 8573-8577
2. Becher, O. J., and Holland, E. C. (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66 (7), 3355-58, discussion 3358-3359
3. Cichowski, K., Shih, T., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., and Jacks, T. (1999). Mouse models of tumor development in neurofibromatosis type I. Science 286, 2172-2176 (Pubitemid 129516295)
4. Daginakatte, G. C., and Gutmann, D. H. (2007). Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16 (9), 1098-1112.
5. Evans, D. G., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., and Moran, A. (2002). Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39 (5), 311-314
6. Goldbrunner, R. H., Wagner, S., Roosen, K., and Tonn, J. C. (2000). Models for assessment of angiogenesis in gliomas. J Neurooncol 50 (1-2), 53-62.
7. Harris, C. C. (1996). p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17 (6), 1187-1198
8. Hawes, J. J., Nerva, J. D., and Reilly, K. M. (2008). Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. J Biomol Screen 13 (8), 795-803.
9. Ichimura, K., Bolin, M. B., Goike, H. M., Schmidt, E. E., Moshref, A., and Collins, V. P. (2000). Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60 (2), 417-424
10. Lyons, S. K. (2005). Advances in imaging mouse tumour models in vivo. J Pathol 205 (2), 194-205.
11. Martin, G. A., Viskochil, D., Bollag, G., McCabe, P. C., Crosier, W. J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R. M., et al. (1990). The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63 (4), 843-849
12. McGillicuddy, L. T., Fromm, J. A., Hollstein, P. E., Kubek, S., Beroukhim, R., De Raedt, T., Johnson, B. W., Williams, S. M., Nghiemphu, P., Liau, L. M., Cloughesy, T. F., Mischel, P. S., Parret, A., Seiler, J., Moldenhauer, G., Scheffzek, K., Stemmer-Rachamimov, A. O., Sawyers, C. L., Brennan, C., Messiaen, L., Mellinghoff, I. K., and Cichowski, K. (2009). Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16 (1), 44-54.
13. McLendon, R., et al. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (7216), 1061-1068
14. McLendon, R. E., and Halperin, E. C. (2003). Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98 (8), 1745-1748
15. Menon, A., Anderson, K., Riccardi, V. M., Chung, R. Y., Whaley, J. M., Yandell, D. W., Farmer, G. E., Freiman, R. N., Lee, J. K., Li, F. P., et al. (1990). Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 87, 5435-5439
16. Momota, H., and Holland, E. C. (2005). Bioluminescence technology for imaging cell proliferation. Curr Opin Biotechnol 16 (6), 681-686
17. Ohgaki, H. (2005). Genetic pathways to glioblastomas. Neuropathology 25 (1), 1-7.
18. Parr, M. J., Manome, Y., Tanaka, T., Wen, P., Kufe, D.W., Kaelin, W. G. Jr., and Fine, H. A. (1997). Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3 (10), 1145-1149
19. Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L., Olivi, A., McLendon, R., Rasheed, B. A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D. A., Tekleab, H., Diaz., L. A. Jr., Hartigan, J., Smith, D. R. Strausberg, R. L., Marie, S. K., Shinjo, S. M., Yan, H., Riggins, G. J., Bigner, D. D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., and Kinzeler, K. W. (2008). An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science 321 (5897), 1807-1812
20. Pollack, I. F., Shultz, B., and Mulvihill, J. J. (1996). The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 46 (6), 1652-1660
21. Reilly, K. M., Broman, K. W., Bronson, R. T., Tsang, S., Loisel, D. A., Christy, E. S., Sun, Z., Diehl, J., Munroe, D. J., and Tuskan, R. G. (2006). An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res 66 (1), 62-68.
22. Reilly, K. M., Loisel, D. A., Bronson, R. T., McLaughlin, M. E., and Jacks, T. (2000). Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26 (1), 109-113
23. Reilly, K. M., Tuskan, R. G., Christy, E., Loisel, D. A., Ledger, J., Bronson, R. T., Smith, C. D., Tsang, S., Munroe, D. J., and Jacks, T. (2004). Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A 101 (35), 13008-13013
24. Riccardi, V. M. (1981). Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig Artic Ser 17 (2), 129-145
25. Sorensen, S. A., Mulvihill, J. J., and Nielsen, A. (1986). Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 314 (16), 1010-1015
26. Tomayko, M. M., and Reynolds, C. P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24 (3), 148-154
27. Uhrbom, L., Nerio, E., and Holland, E. C. (2004). Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 10 (11), 1257-1260
28. Vogel, K. S., Klesse, L. J., Velasco-Miguel, S., Meyers, K., Rushing, E. J., and Parada, L. F. (1999). Mouse tumor model for neurofibromatosis type 1. Science 286 (5447), 2176-2179
29. Walrath, J. C., Fox, K., Truffer, E., Gregory Alvord, W., Quiñones, O. A., and Reilly, K. M. (2009). Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner. Mamm Genome 20 (4), 214-223
30. Watanabe, K., Sato, K., Biernat, W., Tachibana, O., von Ammon, K., Ogata, N., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997). Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3 (4), 523-530
31. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J. Jr., Kohn, K. W., Fojo, T., Bates, S. E. Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johnson, G. S., Wittes, R. E., and Paull, K. D. (1997). An informationintensive approach to the molecular pharmacology of cancer. Science 275 (5298), 343-349
32. Weiss, W. A., Israel, M., Cobbs, C., Holland, E., James, C. D., Louis, D. N., Marks, C., McClatchey, A. I., Roberts, T., Van Dyke, T., Wetmore, C., Chiu, I. M., Giovannini, M., Guha, R., Higgins, R. J., Marino, S., Radovanovic, I., Reilly, K, and Aldape, K. (2002). Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 21 (49), 7453-7463
33. Yang, F. C., Ingram, D. A., Chen, S., Zhu, Y., Yuan, J., Yang, X., Knowles, S., Horn, W., Li, Y., Zhang, S., Yang, Y., Vakili, S. T., Yu, M., Burns, D., Robertson, K., Hutchins, G., Parada, L. F., and Clapp, D. W. (2008). Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 135 (3), 437-448
34. Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K., and Parada, L. F. (2002). Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296 (5569), 920-922
35. Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D. K., Mason, R. P., Messing, A., and Parada, L. F. (2005). Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8 (2), 119-130